The Column Group Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 7
- Investments
- 87
- Portfolio
- 22
- Exits
- 23
The Column Group General Information
Description
Founded in 2007, The Column Group is a venture capital investment firm based in San Francisco, California. The firm prefers to invest in early-stage drug discovery companies based on their unique scientific platforms and the potential to deliver multiple breakthrough therapeutics.
Contact Information
Website
www.thecolumngroup.com
Year Founded
2007
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- 1 Letterman Drive
- Building D, Suite DM-900
- San Francisco, CA 94129
- United States
+1 (415) 000-0000
The Column Group Investments (87)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Eikon Therapeutics | 05-May-2021 | Early Stage VC | 00000 | Drug Discovery | Generating Revenue | 0000 0000 00.0 |
| 00000000 | 15-Apr-2021 | 0000 | 00000 | Drug Discovery | Pre-Clinical Trials | 00000 0000000 00.0 |
| 000000 00000000000 | 01-Mar-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 00000 0000000 00.0 |
| 0000000 | 21-Jan-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 0000000 0000000 00.0 |
| 00000 000000000000 | 08-Dec-2020 | 00000 00000 | 0000 | Drug Discovery | Startup | |
| 00 000000000000000 | 30-Sep-2020 | 00000 00000 | 000.00 | Drug Discovery | Startup | 00000 0000000 00.0 |
| 000000 00000000000 | 30-Sep-2020 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - General | 00000 0000000000 |
| 0000000000 | 17-Sep-2020 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 0000000 0000000 00.0 |
| Hexagon Bio | 15-Sep-2020 | Early Stage VC | 0000 | Other Healthcare Technology Systems | Generating Revenue | 00000 0000000 00.0 |
| Casma Therapeutics | 10-Sep-2020 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue | 0000000 000 00.0 |
The Column Group Exits (23)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Nurix | 05-Mar-2021 | Public Investment 2nd Offering | 00000 |
| 0000 0000000000000 | 13-Nov-2020 | 000000 0000000000 | 00000 |
| 00000 | 24-Jul-2020 | 000 | 00000 |
| 0000000000000 0000 | 17-Jun-2020 | 000000 0000000000 | 00000 |
| 0000 0000000000000 | 24-Apr-2020 | 000 | 00000 |
| 0000000000 0000000 | 13-Feb-2020 | 000 | 00000 |
| 0000 000000000000 | 07-Feb-2020 | 000000 0000000000 | 0000 |
| 0000 000000000000 | 01-Nov-2019 | 000 | 0000 |
| Exonics Therapeutics | 16-Jul-2019 | Merger/Acquisition | 00000 |
| Peloton Therapeutics | 11-Jul-2019 | Merger/Acquisition | 00.000 |
The Column Group Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore The Column Group‘s full profile, request access.
Request a free trialThe Column Group Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialThe Column Group Team (29)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| James Evangelista | Chief Financial Officer | San Francisco, CA | |||
| Peter Svennilson | Co-Founder & Managing Partner | 00 | 0 | 0 | San Francisco, CA |
| David Goeddel Ph.D | Managing Partner | 00 | 0 | 0 | San Francisco, CA |
| Robert Tjian Ph.D | Discovery & Science Partner | 0 | 0 | 0 | San Francisco, CA |
| David Baltimore Ph.D | Emeritus Science Partner | 0 | 0 | 0 | San Francisco, CA |
The Column Group Co-Investors (118)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Casdin Capital | 7 | 0 | 0 |
|
|
| EcoR1 Capital | 0 | 0 | 0 |
|
|
| Foresite Capital Management | 0 | 0 | 0 |
|
|
| GV | 0 | 0 |
|
|
|
| Lux Capital Management | 0 | 0 |
|
|